Literature DB >> 18825489

Clinical significance of serum HMGB-1 and sRAGE levels in systemic sclerosis: association with disease severity.

Ayumi Yoshizaki1, Kazuhiro Komura, Yohei Iwata, Fumihide Ogawa, Toshihide Hara, Eiji Muroi, Motoi Takenaka, Kazuhiro Shimizu, Minoru Hasegawa, Manabu Fujimoto, Shinichi Sato.   

Abstract

INTRODUCTION: The high mobility group box 1 protein (HMGB-1)/advanced glycation end products (RAGE) system is recently shown to play an important part in immune/inflammatory disorders. However, the association of this system in systemic sclerosis (SSc) remains unknown.
MATERIALS AND METHODS: To determine clinical association of serum levels of HMGB-1 and soluble RAGE (sRAGE) in patients with SSc, sera from 70 patients with SSc and 25 healthy controls were examined by enzyme-linked immunosorbent assay. Sera from tight-skin mice and bleomycin-induced scleroderma mice, animal models for SSc, were also examined. Skin HMGB-1 and RAGE expression was assessed by immunohistochemistry. RESULTS AND DISCUSSION: Serum HMGB-1 and sRAGE levels in SSc were higher than those in controls. Similarly, HMGB-1 and sRAGE levels in animal SSc models were higher than those in control mice. SSc patients with elevated HMGB-1 and sRAGE levels had more frequent involvement of several organs and immunological abnormalities compared to those with normal levels. Furthermore, HMGB-1 and sRAGE levels correlated positively with modified Rodnan total skin thickness score and negatively with pulmonary function test.
CONCLUSIONS: HMGB-1 and sRAGE expression in the sclerotic skin was more intense than normal skin. These results suggest that elevated serum HMGB-1 and sRAGE levels are associated with the disease severity and immunological abnormalities in SSc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18825489     DOI: 10.1007/s10875-008-9252-x

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  54 in total

1.  Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases.

Authors:  A Taguchi; D C Blood; G del Toro; A Canet; D C Lee; W Qu; N Tanji; Y Lu; E Lalla; C Fu; M A Hofmann; T Kislinger; M Ingram; A Lu; H Tanaka; O Hori; S Ogawa; D M Stern; A M Schmidt
Journal:  Nature       Date:  2000-05-18       Impact factor: 49.962

2.  The receptor for advanced glycation end-products (RAGE) directly binds to ERK by a D-domain-like docking site.

Authors:  Katsuya Ishihara; Kae Tsutsumi; Shiho Kawane; Motowo Nakajima; Tatsuhiko Kasaoka
Journal:  FEBS Lett       Date:  2003-08-28       Impact factor: 4.124

3.  Reishi polysaccharides induce immunoglobulin production through the TLR4/TLR2-mediated induction of transcription factor Blimp-1.

Authors:  Kuo-I Lin; Yeong-Yi Kao; Hui-Kai Kuo; Wen-Bin Yang; Alice Chou; Hsin-Hung Lin; Alice L Yu; Chi-Huey Wong
Journal:  J Biol Chem       Date:  2006-06-23       Impact factor: 5.157

4.  In situ assessment of oxidant and nitrogenic stress in bleomycin pulmonary fibrosis.

Authors:  Simona Inghilleri; Patrizia Morbini; Tiberio Oggionni; Sergio Barni; Carla Fenoglio
Journal:  Histochem Cell Biol       Date:  2005-11-24       Impact factor: 4.304

5.  Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products.

Authors:  J Li; A M Schmidt
Journal:  J Biol Chem       Date:  1997-06-27       Impact factor: 5.157

Review 6.  Is scleroderma an autoantibody mediated disease?

Authors:  Frank C Arnett
Journal:  Curr Opin Rheumatol       Date:  2006-11       Impact factor: 5.006

7.  The extracellular release of HMGB1 during apoptotic cell death.

Authors:  Charles W Bell; Weiwen Jiang; Charles F Reich; David S Pisetsky
Journal:  Am J Physiol Cell Physiol       Date:  2006-07-19       Impact factor: 4.249

8.  HMGB1 is an endogenous immune adjuvant released by necrotic cells.

Authors:  Patrizia Rovere-Querini; Annalisa Capobianco; Paola Scaffidi; Barbara Valentinis; Federica Catalanotti; Marta Giazzon; Ingrid E Dumitriu; Susanne Müller; Matteo Iannacone; Catia Traversari; Marco E Bianchi; Angelo A Manfredi
Journal:  EMBO Rep       Date:  2004-07-23       Impact factor: 8.807

9.  Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes.

Authors:  Kazuo Nakamura; Sho-ichi Yamagishi; Hisashi Adachi; Yayoi Kurita-Nakamura; Takanori Matsui; Takafumi Yoshida; Tsutomu Imaizumi
Journal:  Mol Med       Date:  2007 Mar-Apr       Impact factor: 6.354

10.  The Tight skin mouse: demonstration of mutant fibrillin-1 production and assembly into abnormal microfibrils.

Authors:  C M Kielty; M Raghunath; L D Siracusa; M J Sherratt; R Peters; C A Shuttleworth; S A Jimenez
Journal:  J Cell Biol       Date:  1998-03-09       Impact factor: 10.539

View more
  44 in total

1.  Lipopolysaccharide-Activated Leukocytes Enhance Thymic Stromal Lymphopoietin Production in a Mouse Air-Pouch-Type Inflammation Model.

Authors:  Ryosuke Segawa; Natsumi Mizuno; Takahiro Hatayama; Dong Jiangxu; Masahiro Hiratsuka; Yasuo Endo; Noriyasu Hirasawa
Journal:  Inflammation       Date:  2016-08       Impact factor: 4.092

Review 2.  Intravascular immunity as a key to systemic vasculitis: a work in progress, gaining momentum.

Authors:  G A Ramirez; N Maugeri; M G Sabbadini; P Rovere-Querini; A A Manfredi
Journal:  Clin Exp Immunol       Date:  2014-02       Impact factor: 4.330

3.  The alarmin HMGB-1 influences healing outcomes in fetal skin wounds.

Authors:  Adrienne D Dardenne; Brian C Wulff; Traci A Wilgus
Journal:  Wound Repair Regen       Date:  2013-02-25       Impact factor: 3.617

Review 4.  Pathogenesis of Systemic Sclerosis.

Authors:  Debendra Pattanaik; Monica Brown; Bradley C Postlethwaite; Arnold E Postlethwaite
Journal:  Front Immunol       Date:  2015-06-08       Impact factor: 7.561

Review 5.  Toll-like receptors as therapeutic targets for autoimmune connective tissue diseases.

Authors:  Jing Li; Xiaohui Wang; Fengchun Zhang; Hang Yin
Journal:  Pharmacol Ther       Date:  2013-03-24       Impact factor: 12.310

Review 6.  Calprotectin in rheumatic diseases.

Authors:  Francesca Ometto; Lara Friso; Davide Astorri; Costantino Botsios; Bernd Raffeiner; Leonardo Punzi; Andrea Doria
Journal:  Exp Biol Med (Maywood)       Date:  2016-01-01

7.  Elevated plasma level of HMGB1 is associated with disease activity and combined alterations with IFN-α and TNF-α in systemic lupus erythematosus.

Authors:  Chun-yan Ma; Yu-lian Jiao; Jie Zhang; Qing-rui Yang; Zhi-fen Zhang; Ya-juan Shen; Zi-jiang Chen; Yue-ran Zhao
Journal:  Rheumatol Int       Date:  2010-12-01       Impact factor: 2.631

8.  Multifaceted contribution of the TLR4-activated IRF5 transcription factor in systemic sclerosis.

Authors:  Ryosuke Saigusa; Yoshihide Asano; Takashi Taniguchi; Takashi Yamashita; Yohei Ichimura; Takehiro Takahashi; Tetsuo Toyama; Ayumi Yoshizaki; Koji Sugawara; Daisuke Tsuruta; Tadatsugu Taniguchi; Shinichi Sato
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-23       Impact factor: 11.205

Review 9.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08

10.  Increased expression of S100A8 and S100A9 in patients with diffuse cutaneous systemic sclerosis. A correlation with organ involvement and immunological abnormalities.

Authors:  Xue Xu; Wen-Yu Wu; Wen-Zheng Tu; Hai-Yan Chu; Xiao-Xia Zhu; Min-Rui Liang; Yu Xue; Jiu-Cun Wang; He-Jian Zou
Journal:  Clin Rheumatol       Date:  2013-06-11       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.